Edition:
United States

Five Prime Therapeutics Inc (FPRX.OQ)

FPRX.OQ on NASDAQ Stock Exchange Global Select Market

18.89USD
3:59pm EST
Change (% chg)

$0.55 (+3.00%)
Prev Close
$18.34
Open
$18.30
Day's High
$19.21
Day's Low
$18.30
Volume
193,509
Avg. Vol
238,046
52-wk High
$49.21
52-wk Low
$17.05

Latest Key Developments (Source: Significant Developments)

Five Prime Therapeutics Earns IND Milestone Payment Under Immune Checkpoint Pathways Discovery Collaboration With Bristol-Myers Squibb
Monday, 8 Jan 2018 08:30am EST 

Jan 8 (Reuters) - Five Prime Therapeutics Inc ::FIVE PRIME THERAPEUTICS EARNS IND MILESTONE PAYMENT UNDER IMMUNE CHECKPOINT PATHWAYS DISCOVERY COLLABORATION WITH BRISTOL-MYERS SQUIBB AND ANNOUNCES THAT BMS HAS EXTENDED THE RESEARCH TERM OF THIS COLLABORATION FOR A SECOND TIME.FIVE PRIME THERAPEUTICS INC - MILESTONE FOR ANTIBODY TARGETING TIM-3 TRIGGERS $5 MILLION PAYMENT TO FIVE PRIME.FIVE PRIME- BMS EXTENDS RESEARCH COLLABORATION TERM FOR DEVELOPMENT, COMMERCIALIZATION FOR THERAPEUTICS IN 3 IMMUNE CHECKPOINT PATHWAYS TO MARCH 2019.FIVE PRIME THERAPEUTICS INC - BRISTOL-MYERS SQUIBB WILL ALSO PROVIDE ADDITIONAL FUNDING TO FIVE PRIME FOR EXTENDED TERM OF RESEARCH COLLABORATION.  Full Article

Five Prime Therapeutics Submits Investigational New Drug Application For FPA150
Wednesday, 3 Jan 2018 04:05pm EST 

Jan 3 (Reuters) - Five Prime Therapeutics Inc ::FIVE PRIME THERAPEUTICS SUBMITS INVESTIGATIONAL NEW DRUG APPLICATION FOR NOVEL B7-H4 ANTIBODY FPA150.FIVE PRIME THERAPEUTICS INC - ANTICIPATES INITIATING A PHASE 1 TRIAL OF FPA150 DURING FIRST HALF OF 2018.  Full Article

Five Prime Therapeutics And Zai Lab Announce Exclusive License Agreement
Tuesday, 19 Dec 2017 04:05pm EST 

Dec 19 (Reuters) - Five Prime Therapeutics Inc ::FIVE PRIME THERAPEUTICS AND ZAI LAB ANNOUNCE EXCLUSIVE LICENSE AGREEMENT FOR FPA144 ANTI-FGFR2B ANTIBODY IN GREATER CHINA AND GLOBAL STRATEGIC DEVELOPMENT COLLABORATION.FIVE PRIME THERAPEUTICS - GRANTED ZAI LAB AN EXCLUSIVE LICENSE TO DEVELOP AND COMMERCIALIZE FPA144 IN GREATER CHINA TERRITORY​.FIVE PRIME THERAPEUTICS INC - ‍ZAI LAB WILL BE RESPONSIBLE FOR CONDUCTING PHASE 3 FIGHT TRIAL IN GREATER CHINA​.  Full Article

Bristol-Myers and Five Prime present early-stage data evaluating Cabiralizumab with Opdivo in patients with advanced solid tumors
Thursday, 9 Nov 2017 08:00am EST 

Nov 9 (Reuters) - Five Prime Therapeutics Inc :Bristol-Myers Squibb and Five Prime present phase 1a/1b data evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in patients with advanced solid tumors.Bristol-Myers Squibb - ‍Preliminary results show safety profile of Cabiralizumab plus Opdivo was generally consistent with that of Opdivo monotherapy​.Bristol-Myers Squibb - ‍Early efficacy signal observed in heavily pretreated patients with advanced pancreatic cancer with microsatellite stable disease​.Bristol-Myers Squibb Co - ‍Bristol-Myers Squibb is launching a new study of Cabiralizumab plus Opdivo​.Bristol-Myers Squibb Co - ‍Data show for first time that combining an anti-csf-1 receptor antibody with Opdivo may help restore t cell function​.  Full Article

Five Prime posts Q3 loss of $1.54 per share
Monday, 6 Nov 2017 04:05pm EST 

Nov 6 (Reuters) - Five Prime Therapeutics Inc :Five prime announces third quarter 2017 results and provides business update.Q3 loss per share $1.54.Q3 earnings per share view $-1.24 -- Thomson Reuters I/B/E/S.Five prime therapeutics inc - ‍collaboration revenue for q3 of 2017 increased by $1.6 million to $8.3 million​.  Full Article

Five Prime Therapeutics appoints Aron Knickerbocker as CEO
Monday, 23 Oct 2017 04:05pm EDT 

Oct 23 (Reuters) - Five Prime Therapeutics Inc :Five Prime Therapeutics announces appointment of Aron Knickerbocker as CEO effective January 1, 2018.Five Prime Therapeutics Inc - ‍ selected Aron Knickerbocker to succeed Lewis Williams, as president and CEO​.Five Prime Therapeutics Inc - ‍ Knickerbocker will maintain chief operating officer position until end of 2017​.  Full Article

Five Prime Therapeutics delivered to Inhibrx written notice of termination of agreement
Monday, 28 Aug 2017 04:09pm EDT 

Aug 28 (Reuters) - Five Prime Therapeutics Inc :‍Pursuant to terms of agreement, termination of agreement will become effective on december 27, 2017 (not 'december 27, 201')​.On august 28, 2017, Fiveprime delivered to Inhibrx written notice of termination of agreement for convenience​.  Full Article

Five Prime Therapeutics Q2 loss per share $1.58
Tuesday, 8 Aug 2017 04:05pm EDT 

Aug 8 (Reuters) - Five Prime Therapeutics Inc :Five Prime announces second quarter 2017 results and provides business update.Q2 loss per share $1.58.Q2 earnings per share view $-1.21 -- Thomson Reuters I/B/E/S.Five Prime Therapeutics - ‍cash, cash equivalents and marketable securities totaled $350.7 million on June 30, 2017, compared to $421.7 million on Dec 31, 2016​.Five Prime Therapeutics Inc - ‍collaboration revenue for Q2 of 2017 decreased by $1.4 million to $7.8 million from $9.2 million in Q2 of 2016​.Five Prime Therapeutics Inc - expects full-year 2017 net cash used in operating activities to be less than $120 million​.Five Prime Therapeutics Inc - ‍estimates ending 2017 with slightly less than $300 million in cash, cash equivalents and marketable securities​.  Full Article

Five Prime Therapeutics plans to initiate a global pivotal trial of FPA144 in 2018
Monday, 17 Jul 2017 04:10pm EDT 

July 17 (Reuters) - Five Prime Therapeutics Inc :Five prime Therapeutics initiates patient dosing in phase 1 clinical safety trial evaluating FPA144 in gastric cancer in Japan in preparation for future global late-stage development.Plans to initiate a global pivotal trial of FPA144 in 2018.  Full Article

Five Prime Therapeutics says Lewis Williams to be chairman of board in 2018
Wednesday, 21 Jun 2017 04:05pm EDT 

June 21 (Reuters) - Five Prime Therapeutics Inc ::Five Prime Therapeutics announces Lewis T. "Rusty" Williams plans to transition from CEO to executive chairman of the board in 2018.Says Dr. Williams will remain in his current role until new CEO has been appointed.Five Prime Therapeutics Inc - board will conduct a comprehensive search for a candidate to fill ceo position.Five Prime - Williams has discussed with board his desire to eventually return to executive chairman role while maintaining active role in Five Prime.  Full Article

BRIEF-Five Prime Therapeutics Announces $25 Mln Payment By Bristol-Myers Squibb

* FIVE PRIME THERAPEUTICS ANNOUNCES $25 MILLION PAYMENT BY BRISTOL-MYERS SQUIBB FOR CABIRALIZUMAB DEVELOPMENT MILESTONE